$リネージ セル セラピューティクス(LCTX.US)$Opregen® (Rg6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular Degen...
2
3
報告
Jaguar8 :
Most likely these are the attendees and their companies hahaha
$リネージ セル セラピューティクス(LCTX.US)$Lineage Cell Therapeutics' RG6501 (OpRegen) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
$リネージ セル セラピューティクス(LCTX.US)$looking poised for good things to come.. Upward trend Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases Benzinga Real-time News · 09:06 Lineage Cell Therapeutics Inc (NYSE:LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC:RHHBY) Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy.
リネージ セル セラピューティクスに関するコメント
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular Degen...
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
Benzinga Real-time News
·
09:06
Lineage Cell Therapeutics Inc (NYSE:LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC:RHHBY) Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy.
まだコメントはありません